The overall survival of AML remained poor, however novel therapies have been approved by the FDA, which are CPX-351 (daunorubicin/cytarabine), enasidenib (IDH2 inhibitor), midostaurin (FLT3 inhibitor), and gemtuzumab ozogamicin antibody–drug conjugate (GO) targeting CD33+ cells [8]. Here, CD33 is linked to acute myeloid leukemia.